GLP-1 Drugs Protect the Heart Through Both Blood Pressure Reduction and Weight Loss

Systematic review and meta-analysis of randomized controlled trials from January 2015 to April 2025 evaluating GLP-1RA or dual GLP-1/GIP agonists. Eligible trials reported MACE outcomes and changes in systolic blood pressure and/or weight. Random-effects meta-analyses pooled hazard ratios. Meta-regressions assessed whether BP and weight reductions mediated MACE reduction. Subgroup analyses compared trials using clinical BP versus ambulatory BP monitoring.

There's been a debate about whether GLP-1 drugs protect the heart mainly through weight loss or through blood pressure reduction. This meta-analysis shows both matter independently, but that BP reduction may be a bigger contributor than we thought — we just weren't measuring it accurately enough. This supports using GLP-1 drugs specifically for hypertensive patients, including those with difficult-to-treat resistant hypertension.

This meta-analysis shifts the narrative about how GLP-1 drugs protect the heart. Rather than being primarily 'weight loss drugs that happen to help the heart,' the data suggests BP reduction is a co-equal or even stronger contributor. This has clinical implications: it supports prescribing GLP-1 drugs specifically for patients with hypertension — including resistant hypertension that doesn't respond well to standard BP medications. It also highlights the value of ambulatory BP monitoring over office readings for assessing GLP-1 drug benefits.

Meta-regression can identify associations but cannot prove causation — the analysis cannot definitively determine what proportion of cardiovascular benefit comes from BP reduction versus weight loss versus other mechanisms. The subgroup analysis by BP measurement method depends on how individual trials measured BP, which varied. Individual patient data were not available, limiting the ability to control for all confounders.